Search





Search





Markets
/
Stocks
/
nasdaq-osrh
/

OSR Holdings Inc

OSRH

Add to Watchlist

0.570USD

-0.030-5.02%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

15.16MMarket Cap

15.77P/E TTM



OSR Holdings Inc

0.570

-0.030-5.02%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of OSR Holdings Inc

Currency: USD Updated: 2026-05-15

Key Insights

OSR Holdings Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 201 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.00.In the medium term, the stock price is expected to trend up.The company has shown average stock market performance over the past month, with weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

OSR Holdings Inc's Score

Industry at a Glance

Industry Ranking

201 / 382

Overall Ranking

389 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

OSR Holdings Inc Highlights

StrengthsRisks

OSR Holdings, Inc. is a global healthcare company, dedicated to advancing healthcare outcomes and improving the quality of life for people and their families. The Company is focused on building and developing a portfolio of transformative therapies and healthcare solutions. The Company's operating businesses (through its three wholly owned subsidiaries) include developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases and neurovascular intervention medical device and systems distribution in Korea. The Company’s subsidiary, Vaximm’s flagship asset, VXM01, is a late clinical-stage (NCT037500701) immuno-oncology candidate for glioblastoma. Vaximm has three clinical and pre-clinical drug candidates targeting diseases ranging from glioblastoma to gastrointestinal stromal tumor to ocular diseases. The Company has operations in Europe and South Korea.

Growing

The company is in a growing phase, with the latest annual income totaling USD 2.91M.

Overvalued

The company’s latest PE is 15.77, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 220.68K shares, decreasing 93.19% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 0.00 shares of this stock.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

10.000

Target Price

+1566.39%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of OSR Holdings Inc is 5.72, ranking 320 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 484.06K, representing a year-over-year decrease of 36.41%, while its net profit experienced a year-over-year decrease of 74.27%.

Score

Industry at a Glance

Previous score

5.72

Change



Financials

5.25

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.47

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.84

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.95

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.08

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

OSR Holdings Inc's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of OSR Holdings Inc is 6.10, ranking 319 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is 15.77, which is 8.18% below the recent high of 17.06 and 392.02% above the recent low of -46.05.

Score

Industry at a Glance

Previous score

6.10

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 201/382

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

The current earnings forecast score of OSR Holdings Inc is 8.00, ranking 161 out of 382 in the Biotechnology & Medical Research industry. The average price target is 10.00, with a high of 10.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

10.000

Target Price

+1654.39%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

OSR Holdings Inc

OSRH

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

argenx SE

ARGX

Ionis Pharmaceuticals Inc

IONS

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of OSR Holdings Inc is 2.15, ranking 373 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.84 and the support level at 0.36, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

2.16

Change

-0.01

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.015

Neutral

RSI(14)

48.801

Neutral

STOCH(KDJ)(9,3,3)

34.540

Neutral

ATR(14)

0.131

High Vlolatility

CCI(14)

-40.802

Neutral

Williams %R

68.750

Sell

TRIX(12,20)

0.413

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

0.599

Sell

MA10

0.594

Sell

MA20

0.614

Sell

MA50

0.545

Buy

MA100

0.559

Buy

MA200

0.595

Sell

Institutional Confidence

Currency: USD Updated: 2026-05-15

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BCM Europe AG

7.53M

Bellevue Capital Management LLC

3.12M

Bellevue Global Life Sciences Investors LLC

1.33M

Geode Capital Management, L.L.C.

57.30K

+3.09%

Point72 Asset Management, L.P.

Star Investors

15.03K

Mint Tower Capital Management B.V.

7.50K

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of OSR Holdings Inc is 1.27, ranking 317 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.